Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
PharmacoEconomics
Published in: PharmacoEconomics 6/2008

01-06-2008 | Review Article

Cost of Epilepsy

A Systematic Review

Authors: Adam Strzelczyk, Jens Peter Reese, Dr Richard Dodel, Hajo M. Hamer

Published in: PharmacoEconomics | Issue 6/2008

Login to get access

Abstract

The objective of this review was to overview published cost-of-illness (COI) studies of epilepsy and their methodological approaches. Epilepsy imposes a substantial burden on individuals and society as a whole. The mean prevalence of epilepsy is estimated at 0.52% in Europe, 0.68% in the US, and peaks up to 1.5% in developing countries. Estimation of the economic burden of epilepsy is of pivotal relevance to enable a rational distribution of healthcare resources. This is especially so with the introduction of the newer antiepileptic drugs (AEDs), the marketing of vagal-nerve stimulators and the resurgence of new surgical treatment options, which have the potential to considerably increase the costs of treating epilepsy.
A systematic literature review was performed to identify studies that evaluated direct and indirect costs of epilepsy. Using a standardized assessment form, information on the study design, methodological framework and data sources were extracted from each publication and systematically reported.
We identified 22 studies worldwide on costs of epilepsy. The majority of the studies reflected the costs of epilepsy in Europe (three studies each for the UK and Italy, one study each for Germany, the Netherlands, Switzerland, France and the EU) and the US (four studies), but studies were also available from India (two), Hong Kong, Oman, Burundi, Chile and Mexico. The studies utilized different frameworks to evaluate costs. All used a bottom-up approach; however, only 12 studies (55%) evaluated direct as well as indirect costs. The range for the mean annual direct costs lay between 40 International Dollar purchasing power parities (PPP-$) in rural Burundi and PPP-$4748 (adjusted to 2006 values) in a German epilepsy centre. Recent studies suggest AEDs are becoming the main contributor to direct costs. The mean indirect costs ranged between 12% and 85% of the total annual costs.
Epilepsy is a cost-intensive disorder. A reliable comparison of the different COI studies in epilepsy is not easily feasible, as the evaluated studies show substantial methodological differences with respect to their patient selection criteria, diagnostic stratifications and evaluated costs. Therefore, there is an urgent need for studies that evaluate direct and indirect costs in a standardized fashion.
Literature
1.
Andlin-Sobocki P, Jonsson B, Wittchen HU, et al. Cost of disorders of the brain in Europe. Eur J Neurol 2005 Jun; 12 Suppl. 1: 1–27PubMedCrossRef
2.
Forsgren I, Beghi E, Ekman M. Cost of epilepsy in Europe. Eur J Neurol 2005 Jun; 12 Suppl. 1: 54–58PubMedCrossRef
3.
Hauser WA, Annegers JF, Kurland LT. Prevalence of epilepsy in Rochester, Minnesota: 1940–1980. Epilepsia 1991 Jul–Aug; 32 (4): 429–445PubMedCrossRef
4.
Preux PM, Druet-Cabanac M. Epidemiology and aetiology of epilepsy in sub-Saharan Africa. Lancet Neurol 2005 Jan; 4 (1): 21–31PubMedCrossRef
5.
Begley CE, Annegers JF, Lairson DR, et al. Cost of epilepsy in the United States: a model based on incidence and prognosis. Epilepsia 1994 Nov–Dec; 35 (6): 1230–1243PubMedCrossRef
6.
Jallon P. Prognosis of epilepsies. Montrouge: John Libbey Eurotext, 2003
7.
Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000 Feb 3; 342 (5): 314–319PubMedCrossRef
8.
9.
Ben-Menachem E, Hellstrom K, Verstappen D. Analysis of direct hospital costs before and 18 months after treatment with vagus nerve stimulation therapy in 43 patients. Neurology 2002 Sep 24; 59 (6 Suppl. 4): S44–S47PubMedCrossRef
10.
Cramer JA, Ben-Menachem E, French J. Review of treatment options for refractory epilepsy: new medications and vagal nerve stimulation. Epilepsy research 2001 Nov; 47 (1-2): 17–25PubMedCrossRef
11.
Swinkels WA, Kuyk J, van Dyck R, et al. Psychiatric comorbidity in epilepsy. Epilepsy Behav 2005 Aug; 7 (1): 37–50PubMedCrossRef
12.
Gaitatzis A, Trimble MR, Sander JW. The psychiatric comorbidity of epilepsy. Acta Neurol Scand 2004 Oct; 110 (4): 207–220PubMedCrossRef
13.
14.
Jacoby A, Baker GA, Steen N, et al. The clinical course of epilepsy and its psychosocial correlates: findings from a UK community study. Epilepsia 1996 Feb; 37 (2): 148–161PubMedCrossRef
15.
16.
Smeets VM, van Lierop BA, Vanhoutvin JP, et al. Epilepsy and employment: literature review. Epilepsy Behav 2007 May; 10 (3): 354–362PubMedCrossRef
17.
18.
19.
Begley CE, Annegers JF, Lairson DR, et al. Estimating the cost of epilepsy. Epilepsia 1999; 40 Suppl. 8: 8–13PubMedCrossRef
20.
Kotsopoulos IA, Evers SM, Ament AJ, et al. Estimating the costs of epilepsy: an international comparison of epilepsy cost studies. Epilepsia 2001 May; 42 (5): 634–640PubMedCrossRef
21.
Brunetti M, Pagano E, Garattini L. The economic cost of epilepsy: a review. Ital J Neurol Sci 1998 Apr; 19 (2): 116–119PubMedCrossRef
22.
23.
Drummond M. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 2005
24.
Millennium Development Goals Indicators [online]. Available from URL: http://​mdgs.​un.​org/​unsd/​mdg [Accessed 2007 Nov 15]
25.
Cockerell OC, Hart YM, Sander JW, et al. The cost of epilepsy in the United Kingdom: an estimation based on the results of two population-based studies. Epilepsy Res 1994 Jul; 18 (3): 249–260PubMedCrossRef
26.
Jacoby A, Buck D, Baker G, et al. Uptake and costs of care for epilepsy: findings from a UK regional study. Epilepsia 1998 Jul; 39 (7): 776–786PubMedCrossRef
27.
Swingler RJ, Davidson DL, Roberts RC, et al. The cost of epilepsy in patients attending a specialist epilepsy service. Seizure 1994 Jun; 3 (2): 115–120PubMedCrossRef
28.
Beghi E, Garattini L, Ricci E, et al. Direct cost of medical management of epilepsy among adults in Italy: a prospective cost-of-illness study (EPICOS). Epilepsia 2004 Feb; 45 (2): 171–178PubMedCrossRef
29.
Berto P, Tinuper P, Viaggi S. Cost-of-illness of epilepsy in Italy: data from a multicentre observational study (Episcreen). Pharmacoeconomics 2000; 17 (2): 197–208PubMedCrossRef
30.
Tetto A, Manzoni P, Millul A, et al. The costs of epilepsy in Italy: a prospective cost-of-illness study in referral patients with disease of different severity. Epilepsy Res 2002 Feb; 48 (3): 207–216PubMedCrossRef
31.
Hamer HM, Spottke A, Aletsee C, et al. Direct and indirect costs of refractory epilepsy in a tertiary epilepsy center in Germany. Epilepsia 2006 Dec; 47 (12): 2165–2172PubMedCrossRef
32.
Kotsopoulos I A, Evers SM, Ament AJ, et al. The costs of epilepsy in three different populations of patients with epilepsy. Epilepsy Res 2003 May; 54 (2-3): 131–140PubMedCrossRef
33.
Gessner U, Sagmeister M, Horisberger B. The costs of epilepsy in Switzerland. Int J Health Sci 1993; 4 (3): 121–128
34.
De Zelicourt M, Buteau L, Fagnani F, et al. The contributing factors to medical cost of epilepsy: an estimation based on a French prospective cohort study of patients with newly diagnosed epileptic seizures (the CAROLE study). Active Coordination of the Longitudinal Observational Network in Epilepsy. Seizure 2000 Mar; 9 (2): 88–95PubMedCrossRef
35.
Begley CE, Famulari M, Annegers JF, et al. The cost of epilepsy in the United States: an estimate from population-based clinical and survey data. Epilepsia 2000 Mar; 41 (3): 342–351PubMedCrossRef
36.
Halpern M, Rentz A, Murray M. Cost of illness of epilepsy in the US: comparison of patient-based and population-based estimates. Neuroepidemiology 2000 Mar–Apr; 19 (2): 87–99PubMedCrossRef
37.
Murray MI, Halpern MT, Leppik IE. Cost of refractory epilepsy in adults in the USA. Epilepsy Res 1996 Mar; 23 (2): 139–148PubMedCrossRef
38.
Krishnan A, Sahariah SU, Kapoor SK. Cost of epilepsy in patients attending a secondary-level hospital in India. Epilepsia 2004 Mar; 45 (3): 289–291PubMedCrossRef
39.
Thomas SV, Sarma PS, Alexander M, et al. Economic burden of epilepsy in India. Epilepsia 2001 Aug; 42 (8): 1052–1060PubMedCrossRef
40.
Mak W, Fong JK, Cheung RT, et al. Cost of epilepsy in Hong Kong: experience from a regional hospital. Seizure 1999 Dec; 8 (8): 456–464PubMedCrossRef
41.
Al-Zakwani I, Hanssens Y, Deleu D, et al. Annual direct medical cost and contributing factors to total cost of epilepsy in Oman. Seizure 2003 Dec; 12 (8): 555–560PubMedCrossRef
42.
Nsengiyumva G, Dmet-Cabanac M, Nzisabira L, et al. Economic evaluation of epilepsy in Kiremba (Burundi): a case-control study. Epilepsia 2004 Jun; 45 (6): 673–677PubMedCrossRef
43.
Mesa T, Mesa JT, Guarda J, et al. The direct costs of epilepsy in a Chilean population [in Spanish]. Rev Neurol 2007 Jun 16–30; 44 (12): 710–714PubMed
44.
Garcia-Contreras F, Constantino-Casas P, Castro-Rios A, et al. Direct medical costs for partial refractory epilepsy in Mexico. Arch Med Res 2006 Apr; 37 (3): 376–383PubMedCrossRef
45.
WHO. Epilepsy: historical overview [fact sheet no. 168]. Geneva: WHO, 2001
46.
Meinardi H, Scott RA, Reis R, et al. The treatment gap in epilepsy: the current situation and ways forward. Epilepsia 2001 Jan; 42 (1): 136–149PubMedCrossRef
47.
Scott RA, Lhatoo SD, Sander JW. The treatment of epilepsy in developing countries: where do we go from here? Bull World Health Organ 2001; 79 (4): 344–351PubMed
48.
WHO. Epilepsy: social consequences and economic aspects [fact sheet no. 166]. Geneva: WHO, 2001
49.
50.
Koopmanschap MA, Rutten FF, van Ineveld BM, et al. The friction cost method for measuring indirect costs of disease. J Health Econ 1995 Jun; 14 (2): 171–189PubMedCrossRef
51.
Drummond MF. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press, 2005
52.
Goeree R, O’Brien BJ, Blackhouse G, et al. The valuation of productivity costs due to premature mortality: a comparison of the human-capital and friction-cost methods for schizophrenia. Can J Psychiatry 1999 Jun; 44 (5): 455–463PubMed
53.
Graf von der Schulenburg J-M, Hoffmann C. Review of European guidelines for economic evaluation of medical technologies and pharmaceuticals. HEPAC 2000; 1: 2–8CrossRef
54.
Tsiropoulos I, Gichangi A, Andersen M, et al. Trends in utilization of antiepileptic drugs in Denmark. Acta Neurol Scand 2006 Jun; 113 (6): 405–411PubMedCrossRef
55.
Andermann F, Duh MS, Gosselin A, et al. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia 2007 Mar; 48 (3): 464–469PubMedCrossRef
56.
Heaney DC, Sander JW. Antiepileptic drugs: generic versus branded treatments. Lancet Neurol 2007 May; 6 (5): 465–468PubMedCrossRef
57.
Kramer G, Steinhoff BJ, Feucht M, et al. Experience with generic drugs in epilepsy patients: an electronic survey of members of the German, Austrian and Swiss branches of the ILAE. Epilepsia 2007 Mar; 48 (3): 609–611PubMedCrossRef
58.
Ekman M, Forsgren L. Economic evidence in epilepsy: a review. Eur J Health Econ 2004 Oct; 5 Suppl. 1: S36–S42PubMedCrossRef
59.
60.
Begley CE, Beghi E, Beran RG, et al. ILAE Commission on the Burden of Epilepsy, Subcommission on the Economic Burden of Epilepsy: final report 1998–2001. Epilepsia 2002 Jun; 43 (6): 668–673PubMedCrossRef
61.
Schöffski O, Schulenburg J. Gesundheitsökonomische Evaluationen. 3, vollständig überarb. Aufl. ed. Berlin: Springer, 2007
62.
Begley CE, Annegers JF, Lairson DR, et al. Methodological issues in estimating the cost of epilepsy. Epilepsy Res 1999 Jan; 33 (1): 39–55PubMedCrossRef
63.
Frost FJ, Hurley JS, Petersen HV, et al. A comparison of two methods for estimating the health care costs of epilepsy. Epilepsia 2000 Aug; 41 (8): 1020–1026PubMedCrossRef
Metadata
Title
Cost of Epilepsy
A Systematic Review
Authors
Adam Strzelczyk
Jens Peter Reese
Dr Richard Dodel
Hajo M. Hamer
Publication date
01-06-2008
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 6/2008
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200826060-00002

Other articles of this Issue 6/2008

PharmacoEconomics 6/2008 Go to the issue

Original Research Article

Cost-Utility Analysis of Varenicline versus Existing Smoking Cessation Strategies using the BENESCO Simulation Model

Review Article

Guidelines for Conducting Pharmaceutical Budget Impact Analyses for Submission to Public Drug Plans in Canada

Original Research Article

Cost Effectiveness of the German Screen-and-Treat Strategy for Postmenopausal Osteoporosis

Leading Article

Economic Burden of Heart Failure in the Elderly